ArticleNature communications2019
Aurora-A mediated phosphorylation of LDHB promotes glycolysis and tumor progression by relieving the substrate-inhibition effect.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 4 pooled it
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 4 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Research trends on lactate in cancer: a bibliometric analysis and comprehensive review (2015-2024).Frontiers in immunology · 2025Pooled it
- Aberrant Energy Metabolism in Tumors and Potential Therapeutic Targets.Genes, chromosomes & cancer · 2024Pooled it
- Interplay Between Glucose Metabolism and Chromatin Modifications in Cancer.Frontiers in cell and developmental biology · 2021Pooled it
- Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis.Cancer medicine · 2020Pooled it
- LDH isozymes as targets for cancer therapy.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Lactate as a Signaling Molecule in the Tumor Microenvironment: Implications for Cancer Progression.Biochemical genetics · 2026Review
- WDR12 Promotes Glucose Metabolism via PFKFB4 Upregulation in Gastric Cancer.Cancer science · 2026Article
- Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities.Experimental hematology & oncology · 2026Review
- [3-Npj imaging · 2026Article
- AURKA-mediated destabilization of SAPS3 drives ferroptosis evasion via 7-dehydrocholesterol biosynthesis in colorectal cancer.Cell death & disease · 2026Article
- Article
- Integrating Single-Cell and RNA Sequencing to Predict Glioma Prognosis Through Lactylation.International journal of molecular sciences · 2026Article
- The moonlighting functions of glycolytic enzymes in tumorigenesis.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Lactylation in cancer: molecular mechanisms and advances in clinical study.Molecular cancer · 2026Review
- A Cuproptosis-Glycolysis Signature Predicts Prognosis and Highlights AURKA as a Therapeutic Target in ccRCC.Human mutation · 2026Article
- Poly-ADP-ribosylation modulated by poly(ADP-ribose) polymerase 1 is associated with glucose metabolism in colorectal cancer cells.Translational oncology · 2026Article
- Glucose and Lactate, Starters or Intermediates of Cancer Metabolic Rewiring.Advances in experimental medicine and biology · 2026Review
- CUEDC1 promotes glycolytic metabolism reprogramming through the CUEDC1/CACNG4/PI3K axis to promote ER-positive breast cancer growth.Cellular & molecular biology letters · 2025Article
- Narciclasine as a Novel Treatment for Lung Cancer and Malignant Pleural Mesothelioma: Insights from 3D Tumor Spheroid Models.International journal of molecular sciences · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 3 institutions in 1 country.
Aoxing ChengHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Peng ZhangHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.ORCID http://orcid.org/0000-0002-3993-3321
Bo WangState Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Dongdong YangHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Xiaotao DuanState Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Yongliang JiangHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Tian XuHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Ya JiangHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Jiahui ShiHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Chengtao DingHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Gao WuHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Zhihong SangInstitute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing, China.
Qiang WuDepartment of Pathology, Anhui Medical University, Hefei, China.
Hua WangDepartment of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID http://orcid.org/0000-0002-2605-5697
Mian WuHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.ORCID http://orcid.org/0000-0002-2714-0500
Zhiyong ZhangHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Xin PanInstitute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing, China.ORCID http://orcid.org/0000-0002-1982-2261
Yue-Yin PanDepartment of Medical Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Ping GaoHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Huafeng ZhangHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Cong-Zhao ZhouHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.ORCID http://orcid.org/0000-0002-6881-7151
Jing GuoHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. jguo2013@ustc.edu.cn.ORCID http://orcid.org/0000-0002-0470-5417
Zhenye YangHefei National Laboratory for Physical Sciences at Microscale, CAS key Laboratory of Innate Immunity and Chronic Disease, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. zhenye@ustc.edu.cn.ORCID http://orcid.org/0000-0001-7797-5891
University of Science and Technology of China · CNAnhui Medical University · CNNational Center of Biomedical Analysis · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpressed Aurora-A kinase promotes tumor growth through various pathways, but whether Aurora-A is also involved in metabolic reprogramming-mediated cancer progression remains unknown. Here, we report that Aurora-A directly interacts with and phosphorylates lactate dehydrogenase B (LDHB), a subunit of the tetrameric enzyme LDH that catalyzes the interconversion between pyruvate and lactate. Aurora-A-mediated phosphorylation of LDHB serine 162 significantly increases its activity in reducing pyruvate to lactate, which efficiently promotes NAD
Indexed as
GlycolysisAnimalsAurora Kinase AAzepinesCell Line, TumorHEK293 CellsHeLa CellsHumansIsoenzymesLactic AcidL-Lactate DehydrogenaseMaleMice, Inbred BALB CMice, NudeMutationNeoplasmsAurora Kinase AAzepinesIsoenzymeslactate dehydrogenase 1Lactic AcidL-Lactate DehydrogenaseMLN 8237PyrimidinesPyruvic AcidSerine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.